A phase 1 study of CD38 CAR-T to treat patients with Multiple Myeloma.

Trial Profile

A phase 1 study of CD38 CAR-T to treat patients with Multiple Myeloma.

Planning
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs CAR-T cell therapies (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 07 Feb 2018 New trial record
    • 05 Feb 2018 According to a Sorrento Therapeutics media release, IND submission is for the drug is anticipated in 1Q2018 and the first patient treatment is expected by mid 2018. Study may complete within 12 months after initiation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top